Journal profile · Biotechnology & Applied Microbiology
Human Gene Therapy
ISSN 1043-0342 · eISSN 1557-7422 · Mary Ann Liebert Inc. · UNITED STATES · Semimonthly · Founded 1990
Human Gene Therapy: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.59; hybrid open access; review 4–8 weeks (community reports); community-reported acceptance: fairly hard; 106 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Human Gene Therapy is published by Mary Ann Liebert Inc. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Virus-based gene therapy research, CRISPR and Genetic Engineering and RNA Interference and Gene Delivery, together about 49.1% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.
Source: LetPub
Research area (LetPub): Biotechnology & Applied Microbiology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology27%
- CRISPR and Genetic EngineeringBiochemistry, Genetics and Molecular Biology11.3%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology10.8%
- CAR-T cell therapy researchMedicine8.9%
- Viral Infectious Diseases and Gene Expression in InsectsBiochemistry, Genetics and Molecular Biology5.5%
- Biomedical Ethics and RegulationMedicine5.3%
- Immunotherapy and Immune ResponsesImmunology and Microbiology3.3%
- Viral gastroenteritis research and epidemiologyMedicine2.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biotechnology & Applied Microbiology | Zone 2 |
| Minor | Genetics & Heredity | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biotechnology & Applied Microbiology | Zone 3 |
| Minor | Genetics & Heredity | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biotechnology & Applied Microbiology | Zone 2 |
| Minor | Genetics & Heredity | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.59LetPub ·
- CiteScore 2026-06
- 7.4LetPub ·
- SJR 2026-06
- 1.28LetPub ·
- SNIP 2026-06
- 0.8LetPub ·
- h-index
- 142LetPub ·
- h-index
- 187OpenAlex ·
- i10-index
- 3,764OpenAlex ·
- 2-year mean citedness
- 3.86OpenAlex ·
- Self-citation rate
- 4.3%LetPub ·
- Share of gold OA articles
- 16.54%LetPub ·
Volume
- Articles per year
- 80LetPub ·
Articles by year OpenAlex count · 6,209 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 95 | 22 | 17 |
| 2025 | 106 | 35 | 288 |
| 2024 | 84 | 37 | 796 |
| 2023 | 133 | 57 | 1,349 |
| 2022 | 125 | 49 | 1,648 |
| 2021 | 153 | 52 | 2,131 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- Fairly hardLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Mary Ann Liebert Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Semimonthly
- Founded
- 1990
- ISSN
- 1043-0342
- Electronic ISSN
- 1557-7422
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Human Gene Therapy
What CAS zone is Human Gene Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Human Gene Therapy is in Zone 3 of Medicine, and in Zone 2 of the minor category Biotechnology & Applied Microbiology / Genetics & Heredity / Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Human Gene Therapy?
The latest impact factor listed by LetPub is 4.59; CiteScore 7.4, h-index 187.
How long does peer review take at Human Gene Therapy?
Authors report an average review time of 4–8 weeks; the community-reported acceptance is “Fairly hard”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Human Gene Therapy?
According to LetPub and DOAJ records, Human Gene Therapy is indexed in SCIE and Scopus.
Is Human Gene Therapy open access, and what is the APC?
Human Gene Therapy is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .